United States · 
What does MPM Capital invest in?
MPM Capital invests most often at Series B and Series A (51% of the rounds on record), in sectors such as Molecules, Ivd and Medical Devices.
MPM Capital highlights
- 01
1 cheques in the last 12 months
- 02
Mostly Series B and Series A: 51% of its rounds
- 03
Sole investor in 8 rounds, median $10M
- 04
23 exits from the portfolio
What they do
Filed 1 private fund offering with the SEC, the most recent in 2020-02From their own website
- Type
- Private equity (from a list, unverified)
- Cheque size
- Up to $150M as they say
- Stages
- Pre-seedSeedSeries ASeries BGrowth
- Sectors
- MoleculesIvdMedical Devices
- Based in
- Boston, United States
- Cold pitches
- Not stated
The record
Every round we can evidence, newest first139 appearances
- 2025
1 round
- Dec
- 2023
1 round
- Oct
- 2019
4 rounds
- Dec
- Nov
- Sept
- Jun
- 2018
2 rounds
- Sept
- Sept
- 2017
2 rounds
- Oct
- May
- 2016
2 rounds
- Aug
- Jul
- 2015
6 rounds
- Dec
- Aug
- Aug
- Apr
- Mar
- Mar
- 2014
4 rounds
- Oct
- Jul
- May
- Apr
- 2013
8 rounds
- Nov
- Oct
- Sept
- Aug
- Jul
- Apr
- Mar
- Mar
- 2012
11 rounds
- Dec
- Nov
- Sept
- Sept
- Jun
- Jun
- Jun
- May
- May
- Feb
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration10 named
AKAlan KellyDirectoriFiling they signed
AKAnsbert Karl GadickeDr. Gadicke is the ManageriFiling they signed
BMBrendan Michael FureyChief Compliance OfficeriForm ADV
CGChristiana Goh BardonDr. Bardon is the Managing Member of the General Partner of the Issuer and the Co-Managing Partner of MPM BioImpact LLC, the Investment ManageriFiling they signed
CWChristopher WolfMr. Wolf is the Chief Financial Officer and Authorized SignatoryiFiling they signed
KLKristen Lee LaguerreMs. Laguerre is the Partner, Finance and Operations and Authorized SignatoryiFiling they signed
LBLuke Basil EvninDr. Evnin is the ManageriFiling they signed
NRNicole RamroopDirectoriFiling they signed
RSRobert Samuel RisoleoGeneral CounseliForm ADV
TTTodd Thomas FoleyManaging DirectoriForm ADV
We also hold 33 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What the register says
From the firm's own filings with the SEC, which it must file accurately by law
$3.6Bassets it managesOct 2026
Registeredinvestment adviserfull reporting to the SEC
- Legal name
- MPM Asset Management LLC
- SEC number
- CRD 148467
Funds on its Form ADV
21 private funds, $3.3B in gross assets · filed Jun 2024
Venture 17Hedge fund and venture capit 2Hedge 2
- Oncology Impact Fund 2, L.P.Hedge fund and venture capit32 investors$826M
- UBS Oncology Impact Fund L.P.Hedge fund and venture capit660 investors$721M
- MPM Bioventures 2018, L.P.Venture43 investors$653M
- MPM Bioventures 2022, L.P.Venture40 investors$345M
- MPM Oncology Innovations Fund L.P.Venture36 investors$170M
- Bioimpact Equities Fund, L.P.Hedge40 investors$154M
- MPM Bioventures 2014, L.P.Venture61 investors$148M
- Bioimpact Equities Master Fund, L.P.Hedge11 investors$99M
- MPM Bioventures IV-QP, L.P.Venture68 investors$52M
- MPM Bioventures 2018 (B), L.P.Venture8 investors$34M
And 11 more on the filing.
What they claim to have backed
From their own portfolio page (on their website)
6 of 11 we have independently watched raise
AstronauTxCullinan OncologyFrontier MedicinesReunion NeuroscienceUmoja-biopharmaelevatebioAktisAshiBioFablePhotysProtego
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.
Exits from the portfolio
Companies it backed that were later bought or listed23 in all
iPierianBought by Bristol-Myers Squibb$175MApr 2014
CeregeneBought by Sangamo BioSciencesUndisclosedAug 2013
VerastemListed$52MJul 2013
Conatus PharmaceuticalsListed$69MJun 2013
Aratana TherapeuticsListed$51MMay 2013
EpizymeListed$60MMay 2013
Portola PharmaceuticalsListed$100MMay 2013
KaloBios PharmaceuticalsListedUndisclosedJan 2013
XoftBought by iCAD$73MDec 2010
Alnara PharmaceuticalsBought by Eli LillyUndisclosedJul 2010
CGI PharmaceuticalsBought by Gilead Sciences$120MJun 2010
AVEO PharmaceuticalsListedUndisclosedMar 2010
CHF SolutionsBought by GambroUndisclosedJan 2010
Neuromed PharmaceuticalsBought by ZalicusUndisclosedDec 2009
Archus OrthopedicsBought by Facet SolutionsUndisclosedNov 2009
Innovative Spinal TechnologiesBought by Theken Spine$9.3MSept 2009
Amphora DiscoveryBought by NanosynUndisclosedJul 2008
CryoCorBought by Boston ScientificUndisclosedMay 2008
Critical Therapeutics,Inc.Bought by Cornerstone TherapeuticsUndisclosedMay 2008
The latest 20 here. An exit counts when it came after the firm's first round in the company. From historical deal records.
Companies it bought
Acquisitions by the firm itself
Kourion TherapeuticsUndisclosedJun 2001